newsfilter
← Latest News
Earnings Call Transcripts·

JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON - TWIST BIOSCIENCE CORP

  • Explicit Guidance:

    • FY2027 revenue guidance of $550–$560 million, reflecting low 20% year-over-year growth.
    • AI Discovery revenue guidance of at least $100 million in FY2027, up from $59 million in FY2026 (a 75%+ actual growth; triple-digit growth was seen in FY2026).
    • Capital expenditures (CapEx) of $75 million in FY2027 and $75 million in FY2028, totaling $150 million over the next two years.
  • Business-Segment Outlook:

    • Total Serviceable Addressable Market (TAM): Expanded to $7 billion in 2026, with a line of sight to $13 billion driven by expansion into new DNA "flavors."
    • AI-Enabled Drug Discovery: Anticipated to be a primary upside driver beyond the $100M guide, limited primarily by current capacity constraints. The business model is shifting from "lumpy" pilot orders to recurring, predictable "run-rate" revenue as customers progress to Phase 3 (production/discovery optimization).
    • NGS & MRD: MRD (Minimal Residual Disease) is expected to be a "huge driver" of growth in FY2027 and beyond. Demand is shifting toward high-sensitivity MRD requiring thousands of probes, leveraging Twist's unique supply advantage.
    • Academic/Government: Expecting potential upside if funding environments rebound; currently gaining meaningful market share even in a tough market due to value proposition (quality, speed, pricing).
    • Cell-Free Synthesis: Recently launched to the entire market; unique competitive advantage as the only scaled supplier for both single-domain and multi-domain proteins, offering a 2-week faster turnaround than cell-based methods.
    • Pooled Discovery: Strategic initiative to shift the market from arrayed discovery to "pooled discovery" to significantly reduce price-per-data-point and increase differentiation.
  • Market and Competitive Outlook:

    • Customer Cohorts: AI adoption is expanding beyond the "Magnificent 7" tech-native firms into traditional pharma (e.g., Eli Lilly's "Tune Lab"), with significant growth opportunity among pharma not yet converted to AI workflows.
    • Modality Evolution: Increasing demand expected as customers graduate from simple single-domain proteins (e.g., VHH) to complex multi-domain antibodies (IgG) and multi-specific IgGs, requiring significantly higher data points.
    • Competitive Positioning: Twist differentiates via the ability to scale pooled DNA synthesis at high quality and speed, a capability competitors cannot match at scale.
    • Market Dynamics: In a challenging economy, customers are more likely to switch suppliers for better value, facilitating Twist's share gains.
  • Macro / Industry Outlook:

    • Economic Environment: Management views the company's value proposition (high quality/speed/price) as "stronger in a tough market" as customers seek cost efficiency.
    • Regulatory/Clinical Trends: Anticipated shift in NGS/MRD standards toward "high-sensitivity" testing, which acts as a volume driver due to the requirement for hundreds to thousands of probes per test.
  • Strategic Initiatives:

    • Capacity Expansion: Adding capacity to support AI drug discovery acceleration, including increasing "riders" from 10 to 16 over the coming year and expanding automation in "Gene Lab 2" and protein characterization equipment.
    • New Product Launches: Full global launch of cell-free synthesis capabilities (previously in early access); expansion of pooled discovery offerings to lower data costs.
    • Infrastructure: Significant CapEx investment phased over 2027–2028 to prevent bottlenecks in high-growth AI segments, specifically targeting synthesis, lab automation, and characterization.
    • Technical Execution: Strategy relies on "copy-pasting" existing operating instruments and managing software integration, minimizing technical risk despite multi-fold capacity scaling.
  • Risks and Headwinds to Outlook:

    • Capacity Constraints: Current ability to realize revenue beyond the $100M AI guide is limited by the time required to onboard new capacity (specifically long lead times on "riders").
    • Software Integration: Identified as the "rate-limiting step" in scaling new capacity; execution risk exists in integrating software to support larger menus and higher throughput.
    • Revenue Volatility in Early Phases: AI discovery revenue can be "lumpy" during Phase 2 (model building) before stabilizing in Phase 3 (production).
    • Unpriced Upside: Guidance does not fully account for potential upside from a broader academic/government funding recovery or accelerated share gains if market conditions improve.
  • Management Tone on the Future:

    • Confidence Level: High confidence in the "march to deliver" and the ability to hit EBITDA break-even. Management expresses "sense of urgency" and excitement regarding AI adoption.
    • Guidance Philosophy: Conservative; guidance is based on demand with a "high degree of confidence." Upside is expected but not included in the formal guidance due to capacity timing.
    • Strategic Confidence: Repeated emphasis on the "compounding plan" of the AI customer lifecycle and the "low technical risk" of scaling via existing validated processes.
  • Miscellaneous:

    • EBITDA: Achieved break-even EBITDA for the first time in the most recent quarter, marking a milestone toward "best-in-class" financial performance compared to peers.
    • Timeline: 2025 revenue was $21 million; 2026 revenue was $59 million (175% growth); 2027 AI guide is $100 million minimum.
Company
TWIST BIOSCIENCE CORP
Keywords
TWIST BIOSCIENCE CORP